FindTrial
Sign In

A cohort study for the role of SMYD2 and miRNA-125b in evaluating the prognosis of renal cell carcinoma

A cohort study for the role of SMYD2 and miRNA-125b in evaluating the prognosis of renal cell carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017391
Enrollment
Unknown
Registered
2018-07-27
Start date
2018-08-10
Completion date
Unknown
Last updated
2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

SMYD2 positive:none
SMYD2 negative:none
miRNA-125b positive:none
miRNA-125b negative:none

Sponsors

Department of Urology Laboratory, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient age>18 year male or female; 3. Patients who underwent total or partial nephrectomy and were diagnosed of clear cell renal cell carcinoma.

Exclusion criteria

Exclusion criteria: 1. Patients whose medical records are incomplete; 2. Patients who have serious heart, lung, or liver disease; 3. Patients who can not be contacted.

Design outcomes

Primary

MeasureTime frame
SMYD2 immunohistochemical staining;miRNA-125b in situ hybridization;—

Countries

China

Contacts

Public ContactXu Hua

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

xuhuawhu@163.com+86 13971051016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026